Press releases
- Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
- ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
- ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
- ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
- ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
- ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
- NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
- N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
More ▼
Key statistics
On Tuesday, Immunitybio Inc (26CA:STU) closed at 6.10, -32.97% below its 52-week high of 9.09, set on May 03, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.90 |
---|---|
High | 6.16 |
Low | 5.90 |
Bid | 6.06 |
Offer | 6.21 |
Previous close | 5.91 |
Average volume | 138.89 |
---|---|
Shares outstanding | 691.57m |
Free float | 153.59m |
P/E (TTM) | -- |
Market cap | 4.58bn USD |
EPS (TTM) | -1.05 USD |
Data delayed at least 15 minutes, as of May 28 2024.
More ▼